<DOC>
	<DOCNO>NCT01853826</DOCNO>
	<brief_summary>To evaluate safety tolerability afatinib ( Giotrif ) patient locally advanced metastatic non-small cell lung cancer ( NSCLC ) harbor EGFR mutation ( ) never treat EGFR-TKI</brief_summary>
	<brief_title>An Open Label Trial Afatinib ( Giotrif ) Treatment-naive ( 1st Line ) Chemotherapy Pre-treated Patients With Locally Advanced Metastatic Non-small Cell Lung Cancer ( NSCLC ) Harboring EGFR Mutation ( )</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>Inclusion criterion : Patients : locally advance metastatic NonSmall Cell Lung Cancer ( NSCLC ) Epidermal Growth Factor Receptor ( EGFR ) mutationpositive result per institution 's test methodology . Adequate organ function , define follow : 1 . Absolute Neutrophil Count ( ANC ) &gt; 1500/mm3 . ( ANC &gt; 1000/mm3 may consider special circumstance benign cyclical neutropenia judge investigator discussion sponsor ) . 2 . Platelet count &gt; 75,000/mm3 3 . Serum creatinine &lt; 1.5 time upper limit normal 4 . Total Bilirubin &lt; 1.5 time upper limit ( institutional ) normal ( Patients Gilbert 's syndrome total bilirubin must &lt; 4 time institutional upper limit normal ) . 5 . Aspartate Amino Transferase ( AST ) Alanine Amino Transferase ( ALT ) &lt; three time upper limit ( institutional ) normal ( ULN ) ( relate liver metastasis &lt; five time ULN ) . Eastern Cooperative Oncology Group ( ECOG ) score 0 2 write informed consent patient guardian prior admission trial consistent International Conference Harmonisation ( ICH ) Good Clinical Practice ( GCP ) guideline local law . Exclusion criterion : Patients : prior treatment EGFR tyrosine kinase inhibitor ( TKI ) anticancer treatment within 2 week prior start trial treatment ( continue use antiandrogens and/or gonadorelin analogue treatment prostate cancer permit ) radiotherapy within 14 day prior drug administration , except follow : 1 . Palliative radiation organ chest may allow 2 week prior drug administration , 2 . Single dose palliative treatment symptomatic metastasis outside allowance discuss sponsor prior enrol . previous concomitant malignancy site , except effectively treat nonmelanoma skin cancer , carcinoma situ cervix , ductal carcinoma situ effectively treat malignancy remission 3 year consider cured . know preexist interstitial lung disease meningeal carcinomatosis symptomatic brain metastasis ( patient asymptomatic brain metastasis , previously treat , eligible provide Stable Disease ( SD ) least 4 week stable dos medication )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>